Literature DB >> 3687888

The antecedents and benefits of achieving abstinence in opioid addicts: a 2.5-year follow-up study.

B J Rounsaville1, T R Kosten, H D Kleber.   

Abstract

This report examines long-term and short-term benefits of achieving abstinence from opioids in a sample of opioid addicts who were reevaluated 2.5 years following seeking treatment. Extensive assessment of drug use history and drug-associated problems had been obtained when the subjects applied for treatment. At follow-up evaluations, detailed information was obtained on intervening course of drug use, treatment, legal problems, psychological problems, social functioning, occupational functioning, and medical status. The results were as follows: (1) Achieving abstinence from illicit opioids was associated with concurrent improvement in other aspects of functioning including reduction of criminal activity, improved medical status, improved social functioning, and reduced abuse of other psychoactive substances. However, many of these improvements were reversed immediately if relapse to opioid use occurred. (2) Achieving abstinence was associated with being in drug treatment, especially treatment in a methadone maintenance program. (3) Achievement of abstinence was not successfully predicted by client characteristics measured at entrance into treatment. (4) Long-range benefits of abstinence were detectable in social functioning even for those who had relapsed at the time of follow-up reevaluation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3687888     DOI: 10.3109/00952998709001511

Source DB:  PubMed          Journal:  Am J Drug Alcohol Abuse        ISSN: 0095-2990            Impact factor:   3.829


  7 in total

1.  What happens in treatment doesn't stay in treatment: cocaine abstinence during treatment is associated with fewer problems at follow-up.

Authors:  Brian D Kiluk; Charla Nich; Katie Witkiewitz; Theresa A Babuscio; Kathleen M Carroll
Journal:  J Consult Clin Psychol       Date:  2014-03-17

2.  The chippers, the quitters, and the highly symptomatic: A 12-month longitudinal study of DSM-5 opioid- and cocaine-use problems in a community sample.

Authors:  Samuel W Stull; Leigh V Panlilio; Landhing M Moran; Jennifer R Schroeder; Jeremiah W Bertz; David H Epstein; Kenzie L Preston; Karran A Phillips
Journal:  Addict Behav       Date:  2019-04-29       Impact factor: 3.913

3.  Changes in health outcomes as a function of abstinence and reduction in illicit psychoactive drug use: a prospective study in primary care.

Authors:  Tae Woo Park; Debbie M Cheng; Christine A Lloyd-Travaglini; Judith Bernstein; Tibor P Palfai; Richard Saitz
Journal:  Addiction       Date:  2015-09       Impact factor: 6.526

4.  What defines a clinically meaningful outcome in the treatment of substance use disorders: reductions in direct consequences of drug use or improvement in overall functioning?

Authors:  Brian D Kiluk; Garrett M Fitzmaurice; Eric C Strain; Roger D Weiss
Journal:  Addiction       Date:  2018-06-27       Impact factor: 6.526

5.  Predictors of Relapse after Inpatient Opioid Detoxification during 1-Year Follow-Up.

Authors:  Harsh Chalana; Tanu Kundal; Varun Gupta; Amandeep Singh Malhari
Journal:  J Addict       Date:  2016-09-18

6.  Improved Quality of Life Following Addiction Treatment Is Associated with Reductions in Substance Use.

Authors:  Victoria Manning; Joshua B B Garfield; Tina Lam; Steve Allsop; Lynda Berends; David Best; Penny Buykx; Robin Room; Dan I Lubman
Journal:  J Clin Med       Date:  2019-09-06       Impact factor: 4.241

7.  Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy Analysis.

Authors:  Anne C Andorn; Barbara R Haight; Sunita Shinde; Paul J Fudala; Yue Zhao; Christian Heidbreder; Susan M Learned; Norma Lynn Fox; Vijay R Nadipelli; David Hassman; Daniel Rutrick
Journal:  J Clin Psychopharmacol       Date:  2020 May/Jun       Impact factor: 3.118

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.